The diagnostic tests rely on circulating tumor cells in patients’ blood. Innogenetics entered into the agreement following the successful conclusion of a feasibility study to convert the current gel-based AdnaDetect products into a routine in vitro diagnostics multiplex platform.
The newly licensed AdnaGen technology can be applied in three distinct cancer diagnostic areas. The first is better prognosis through the identification of circulating tumor cells as a measure of elevated risk of tumor progression. Secondly, the detection of circulating tumor cells provides an indication of the treatment efficacy. Finally, the detection of circulating tumor cells months after therapy may indicate that the treated or resected tumor is relapsing.
Frank Morich, CEO of Innogenetics, commented: “We are pleased with the feasibility results and believe that monitoring circulating tumor cells will provide physicians the means for improved cancer therapy. Cancer diagnostics is an evolving field and Innogenetics wants to capture part of this market by offering solutions for improved patient management, based on our multiplex capabilities and expertise.”